{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"8.1","value":"5.5"},{"comment":"Not estimable due to insufficient data.","groupId":"OG001","lowerLimit":"3.7","upperLimit":"NA","value":"5.5"}]}],"title":"BICR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"8.0","value":"5.6"},{"groupId":"OG001","lowerLimit":"4.9","upperLimit":"9.9","value":"6.9"}]}],"title":"Investigator"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"DoR, defined as time from the initial response (CR or PR) by BICR and Investigator assessment until documented tumor progression or death from any cause. DoR was assessed in the Full Analysis Set at data cut-off date of 01 Nov 2022.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).","id":"OG000","title":"T-DXd 5.4 mg/kg Q3W"},{"description":"Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).","id":"OG001","title":"T-DXd 6.4 mg/kg Q3W"}],"paramType":"MEDIAN","populationDescription":"DoR was assessed in the Full Analysis Set, which included 1 participant who was randomized/registered to T-DXd 6.4 mg/kg Q3W but actually received T-DXd 5.4 mg/kg Q3W.","reportingStatus":"POSTED","timeFrame":"From the first documented evidence of a response (complete or partial) until disease progression or death, up to approximately 19 months.","title":"Duration of Response Following Intravenous Administration of T-DXd in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Overexpressing Metastatic Colorectal Cancer","type":"SECONDARY","unitOfMeasure":"months"}